<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=314834185700910&amp;ev=PageView&amp;noscript=1">

New Update: Healthcare Costs Increasing by Over 60% in Some States. Will you be impacted?

Learn More

Taxation of Expatriates For Abbott Laboratories Employees

conver-img

Healthcare Provider Update: Healthcare Provider for Abbott Laboratories: Abbott Laboratories operates as both a developer and provider of various healthcare products and services, focusing on medical devices, diagnostics, nutrition, and pharmaceuticals. Its health care offerings span from advanced medical devices for chronic disease management to diagnostic equipment and nutritional products aimed at enhancing patient care and outcomes. Potential Healthcare Cost Increases in 2026: As we look towards 2026, healthcare costs are anticipated to surge significantly, primarily driven by the expiration of enhanced federal premium subsidies under the Affordable Care Act (ACA). States may implement record-setting premium hikes, with some rates soaring over 60%. Combined with underlying medical cost inflation and aggressive rate increases from major insurers, consumers could face an alarming rise in out-of-pocket costs-potentially over 75% for many policyholders. This scenario underscores the pressing need for individuals to strategically prepare for the financial landscape in the coming years. Click here to learn more

The HEART of the Matter

As a multinational Abbott Laboratories employee, it is imperative to understand what the HEART act is, and whether it is applicable to you or your loved ones. The Heroes Earnings Assistance and Relief Tax Act of 2008 (the HEART, or 'Heroes' Act), enacted on June 17, 2008, applies new tax rules both to certain U.S. citizens who relinquish their U.S. citizenship and to certain long-term U.S. residents who terminate their U.S. residency.

Relinquishing Citizenship

If you are a Abbott Laboratories employee contemplating relinquishing citizenship, you may want to consider how an individual who has relinquished U.S. citizenship is only recognized as having done so on the earliest of four possible dates:

  1. The date that he or she renounces U.S. nationality before a diplomatic or consular officer of the United States (provided that the voluntary relinquishment is later confirmed by the issuance of a certificate of loss of nationality);
  2. The date that he or she furnishes to the State Department a signed statement of voluntary relinquishment of U.S. nationality confirming the performance of an expatriating act (again, provided that the voluntary relinquishment is later confirmed by the issuance of a certificate of loss of nationality);
  3. The date that the State Department issues a certificate of loss of nationality; or
  4. the date that a U.S. court cancels a naturalized citizen's certificate of naturalization.

Caution: Relinquishment may occur earlier under Treasury regulations with respect to an individual who became at birth both a citizen of the United States and of another country.

Terminating U.S. Residency

An individual is considered to terminate long-term U.S. residency when he or she ceases to be a lawful permanent resident of the United States (i.e., loses his or her green card status through revocation or has been administratively or judicially determined to have abandoned such status). Under the HEART Act, however, an individual ceases to be treated as a lawful permanent resident of the United States for all tax purposes if he or she commences to be treated as a resident of a foreign country under a tax treaty between the United States and such foreign country, does not waive the benefits of the treaty applicable to residents of such foreign country, and notifies the Secretary of the commencement of such treatment. If you are a Abbott Laboratories employee looking to terminate your residency, this information may be applicable when planning your future taxes and having a better idea of the laws regarding this subject.

Individuals Covered

The new tax rules apply to any U.S. citizen who relinquishes citizenship and any long-term resident who terminates U.S. residency, if such individual:

  1. Has an average annual net income tax liability for the five preceding years ending before the date of the loss of U.S. citizenship or residency termination that exceeds $171,000 (in 2020, $168,000 in 2019);
  2. Has a net worth of $2 million or more on such date; or
  3. Fails to certify under penalties of perjury that he or she has complied with all U.S. Federal tax obligations for the preceding five years or fails to submit such evidence of compliance as the Secretary may require.

Exceptions (these exceptions do not apply to an individual who fails to certify under penalties of perjury that he or she has complied with all U.S. Federal tax obligations for the preceding five years or fails to submit such evidence of compliance as the Secretary may require):

  • An individual who was born with citizenship both in the United States and in another country; provided that (1) as of the expatriation date he or she continues to be a citizen of, and is taxed as a resident of, such other country, and (2) he or she has been a resident of the United States (under the substantial presence test of IRC Section 7701(b)(1)(A)(ii)) for not more than 10 taxable years during the 15-year taxable year period ending with the taxable year of expatriation.
  • A U.S. citizen who relinquishes U.S. citizenship before reaching age 18½, provided that he or she was a resident of the United States (under the substantial presence test of section 7701(b)(1)(A)(ii)) for no more than 10 taxable years before such relinquishment.

The Changes of HEART

In General

The HEART Act imposes the following new tax rules on those individuals affected:

  • Such individuals are subject to income tax on the net unrealized gain in their property as if the property had been sold for its fair market value on the day before the expatriation or residency termination ('mark-to-market tax').
  • Gain from the deemed sale is taken into account at that time without regard to other Internal Revenue Code (IRC) provisions.
  • Any loss from the deemed sale generally is taken into account to the extent otherwise provided in the IRC, except that the wash sale rules of Section 1091 do not apply.
  • Any net gain on the deemed sale is recognized to the extent that it exceeds $737,000 (in 2020, up from $725,000 in 2019).
  • Any gains or losses subsequently realized are to be adjusted for gains and losses taken into account under the deemed sale rules, without regard to the exemption.
  • Deferred compensation items, interests in nongrantor trusts, and specified tax deferred accounts are excepted from the mark-to-market tax but are subject to special rules, as noted below.
  • A transfer tax is imposed on certain transfers to U.S. persons from certain U.S. citizens who relinquished their U.S. citizenship and certain long-term U.S. residents who terminated their U.S. residency, or from their estates.

Deferring Payment of Tax

Under the HEART Act, those employed in Abbott Laboratories may elect to defer payment of the tax imposed on the deemed sale of property. Interest is charged for the period the tax is deferred at the rate normally applicable to individual underpayments. The election is irrevocable and is made on a property-by-property basis. Under the election, the deferred tax attributable to a particular property is due when the return is due for the taxable year in which the property is disposed (or, if the property is disposed of in a transaction in which gain is not recognized in whole or in part, at such other time as the Secretary may prescribe). For those eligible to participate in the HEART Act, and also employed in a Abbott Laboratories company, this information is certainly worthy to consider when planning tax deferrals.

The deferred tax attributable to a particular property is a prorated portion of the total mark-to-market tax (calculated according to the ratio of gain attributable to the property to the total gain taken into account for the mark-to-market tax). For Abbott Laboratories employees, the deferral of the mark-to-market tax may not be extended beyond the due date of the return for the taxable year which includes the individual's death.

In order to elect deferral of the mark-to-market tax, the individual is required to furnish a bond to the Secretary. The individual is also required to consent to the waiver of any treaty rights that would preclude the assessment or collection of the tax.

Featured Video

Articles you may find interesting:

Loading...

Special Transfer Tax on Gifts and Bequests

Under the HEART Act, a special transfer tax applies to certain 'covered gifts or bequests' received by a U.S. citizen or resident. For Abbott Laboratories employees, a covered gift or bequest is any property acquired:

  1. By gift directly or indirectly from an individual who is a covered expatriate at the time of such acquisition, or
  2. Directly or indirectly by reason of the death of an individual who was a covered expatriate immediately before death.

A covered gift or bequest, however, does not include any property:

  1. Shown as a taxable gift on a timely filed gift tax return by the covered expatriate,
  2. Included in the gross estate of the covered expatriate for estate tax purposes and shown on a timely filed estate tax return of the estate of the covered expatriate, and
  3. With respect to which a deduction would be allowed under Section 2055, 2056, 2522, or 2523, whichever is appropriate (these sections allow deductions for transfers for charitable purposes or to spouses, for purposes of determining estate and gift taxes).

The tax is calculated at the highest marginal estate tax rate or, if greater, the highest marginal gift tax rate, both as in effect on the date of receipt of the covered gift or bequest. For those employed in a Abbott Laboratories company, the tax is imposed upon the recipient of the covered gift or bequest and is imposed on a calendar-year basis. The tax applies to a recipient of a covered gift or bequest only to the extent that the total value of covered gifts and bequests received by such recipient during a calendar year exceeds the annual exclusion amount in effect under section 2503(b) for that calendar year (currently $15,000). The tax on covered gifts and bequests is reduced by the amount of any gift or estate tax paid to a foreign country with respect to such covered gift or bequest.

Special rules apply to the tax on covered gifts or bequests made to domestic or foreign trusts. In the case of a covered gift or bequest made to a domestic trust, the tax applies as if the trust is a U.S. citizen, and the trust is required to pay the tax. In the case of a covered gift or bequest made to a foreign trust, the tax applies to any distribution from such trust (whether from income or corpus) attributable to such covered gift or bequest to a recipient that is a U.S. citizen or resident, in the same manner as if such distribution were a covered gift or bequest. Such a recipient is entitled to deduct the amount of such tax for income tax purposes to the extent such tax is imposed on the portion of such distribution that is included in the gross income of the recipient.

For purposes of these rules, a foreign trust may elect to be treated as a domestic trust. The election may not be revoked without the Secretary's consent.

Other Special Rules

  •  For deferred compensation items (including qualified plans, 403(b) plans, 457(b) plans, SIMPLE retirement plans, and any interest in a foreign pension plan or retirement arrangement), two rules apply:
  1. If the payer is a U.S. person (or a non-U.S. person who elects to be treated as a U.S. person for purposes of withholding and who meet the requirements prescribed by the Secretary to ensure compliance with the withholding requirements), and the covered expatriate notifies the payor of his status as a covered expatriate and irrevocably waives any claim of withholding reduction under any treaty with the United States, the payer must deduct and withhold from any 'taxable payment' a tax equal to 30 percent of such taxable payment. A taxable payment is subject to withholding to the extent it would be included in the gross income of a citizen or resident of the United States. A deferred compensation item that is subject to the 30 percent withholding requirement is subject to tax under IRC Section 871.
  1. Otherwise, an amount equal to the present value of the covered expatriate's deferred compensation item is treated as having been received on the day before the expatriation date. In the case of a deferred compensation item that is subject to IRC Section 83, the item is treated as becoming transferable and no longer subject to a substantial risk of forfeiture on the day before the expatriation date. Appropriate adjustments shall be made to subsequent distributions.

These deemed distributions are not subject to early distribution tax.

  • For 'specified tax deferred accounts' (IRAs, 529 plans, Coverdell ESAs, HSAs, and Archer MSAs), a covered expatriate is treated as receiving a distribution of his entire interest in these accounts on the day before his or her expatriation date. Appropriate adjustments are made for subsequent distributions to take into account this treatment. As with deferred compensation items, these deemed distributions are not subject to early distribution tax.
  • For the portion of any trust for which the covered expatriate is treated as the owner under the grantor trust provisions of the IRC (determined immediately before the expatriation date) the assets held by that portion of the trust are subject to the mark-to-market tax. If a trust that is a grantor trust immediately before the expatriation date subsequently becomes a nongrantor trust, such trust remains a grantor trust for purposes of the provision.

  • For trusts ('nongrantor trusts') with respect to which the covered expatriate is a beneficiary on the day before the expatriation date, the trustee must deduct and withhold from any direct or indirect distribution to a covered expatriate an amount equal to 30 percent of the portion of the distribution which would be includable in the gross income of the covered expatriate if the covered expatriate continued to be subject to tax as a citizen or resident of the United States. The portion of the distribution that is subject to the 30 percent withholding requirement is subject to tax under IRC Section 871. The covered expatriate is treated as having waived any right to claim any reduction in withholding under any treaty with the United States. If the trust distributes appreciated property to a covered expatriate, the trust must recognize gain as if the property were sold to the covered expatriate at its fair market value. If a trust that is a non-grantor trust immediately before the expatriation date subsequently becomes a grantor trust of which a covered expatriate is treated as the owner, directly or indirectly, such conversion is treated as a distribution to the extent of the portion of the trust of which the covered expatriate is treated as the owner.
    • Any period for acquiring property which results in the reduction of gain recognized with respect to property disposed of by the taxpayer terminates on the day before the expatriation date. This rule applies to certain incomplete transactions such as deferred like-kind exchanges and involuntary conversions.
    • Any extension of time for payment of tax ceases to apply on the day before relinquishment of citizenship or termination of residency, and the unpaid portion of such tax becomes due and payable at the time and in the manner prescribed by the Secretary.
    • For purposes of determining the tax imposed under the mark-to-market tax, property that was held by an individual on the date that such individual first became a resident of the United States is treated as having a basis on such date of not less than the fair market value of such property on such date. An individual may make an irrevocable election not to have this rule apply.

    How does the Abbott Laboratories Annuity Retirement Plan (ARP) determine the eligibility requirements for employees, and how can potential changes in federal regulations impact these requirements? Employees of Abbott Laboratories may need to understand the nuances of eligibility, particularly regarding age and service criteria. Changes in laws governing retirement benefits could pose questions about continued eligibility and could affect when employees can begin pension payments.

    Eligibility Requirements & Impact of Federal Regulations: Employees at Abbott Laboratories become eligible for the ARP by being part of a participating division, being at least 21 years old, and residing in the U.S. (with certain exceptions for U.S. employees abroad). Changes in federal regulations could potentially alter these eligibility criteria, especially since such rules often influence age and service requirements for retirement plans. Any changes in legislation regarding retirement benefits might necessitate adjustments in eligibility rules, affecting when employees can begin receiving pension payments.

    Can you explain the significance of Vesting Service in the context of the Abbott Laboratories Annuity Retirement Plan? Employees often wonder how their years of service influence their benefit eligibility and the amount they can expect. Understanding the elements that constitute Vesting Service, and the implications of terminating employment before achieving vesting, is crucial for Abbott Laboratories employees planning for retirement.

    Significance of Vesting Service: Vesting Service at Abbott Laboratories refers to the time an employee must accumulate to gain entitlement to pension benefits, irrespective of continued employment. This service is critical as it determines the security of an employee's future benefits and the degree of an employee's investment in the company's pension plan. Employees who terminate employment prior to achieving full vesting lose entitlement to accrued pension benefits, making understanding and accruing Vesting Service essential for long-term financial planning.

    In what ways does the calculation of Final Average Pay play a role in determining retirement benefits under the Abbott Laboratories Annuity Retirement Plan? The methodology used to calculate an employee's Final Average Pay can significantly impact the retirement income they receive. Employees at Abbott Laboratories should consider how their earnings history and the inclusion or exclusion of certain payments factor into their anticipated benefits.

    Role of Final Average Pay in Benefit Calculation: Final Average Pay (FAP) is crucial in determining the pension benefits under the ARP as it represents the average of an employee’s highest earnings over a specified period. Abbott’s ARP calculates pension based on a percentage of the FAP, multiplied by years of eligible service. This calculation means that higher earnings towards the end of an employee's career can significantly increase the pension benefits, incentivizing employees to maximize their earnings potential in their final working years.

    What optional forms of payment are available to employees upon retirement under the Abbott Laboratories Annuity Retirement Plan, and how do these choices affect overall pension benefits? Abbott Laboratories employees need to evaluate whether to choose single or joint survivor annuities, among other options, as these decisions can have long-term financial implications for both themselves and their beneficiaries.

    Optional Forms of Payment at Retirement: The ARP offers various payment options upon retirement, including single and joint survivor annuities, which affect the benefit's distribution and longevity. These choices impact financial planning for retirement, particularly in ensuring that a spouse or beneficiary may continue to receive benefits after the retiree's death. The selection between these options should align with personal financial needs and considerations for dependents' security.

    Different employees may have varying perspectives on the importance of early retirement options offered by Abbott Laboratories. What are the qualifications for early special retirement, and how does this option affect retirement income? Employees contemplating retirement before the standard age should understand how factors such as age, years of service, and the specific provisions of the Abbott Laboratories Annuity Retirement Plan influence their benefits.

    Early Retirement Qualifications and Impacts: Early retirement under the ARP is available to employees who meet specific age and service criteria, allowing them to retire with reduced benefits before reaching the normal retirement age. This option can significantly affect retirement income, depending on the number of years ahead of normal retirement age the employee chooses to retire, making it crucial for employees to understand the financial trade-offs involved in retiring early.

    How does the Abbott Laboratories Annuity Retirement Plan ensure compliance with the Employee Retirement Income Security Act (ERISA), and what rights do employees have under this act? Abbott Laboratories employees should be informed about their rights regarding plan documentation, required disclosures, and recourse in the event of disputes pertaining to their retirement benefits.

    ARP Compliance with ERISA: The ARP is designed to comply with the Employee Retirement Income Security Act (ERISA), providing employees with rights to information about plan features and funding, benefits accrual, and recourse in case of disputes. Compliance with ERISA ensures that employees' retirement benefits are protected under federal law, offering a framework for security and transparency in their retirement planning.

    How do Abbott Laboratories employees who experience a medical leave of absence or disability maintain their retirement service credits under the Annuity Retirement Plan? Understanding the interaction between long-term disability benefits, medical leave, and retirement plan participation is essential for employees navigating health-related issues while planning for their retirement.

    Impact of Medical Leave or Disability on Retirement Credits: Employees on medical leave or disability continue to accrue service credits under the ARP, ensuring that such periods do not adversely affect their pension benefits. This protection helps employees who are temporarily unable to work due to health issues maintain their trajectory towards earning full retirement benefits.

    Given the potential for changes to the Abbott Laboratories Annuity Retirement Plan, how can employees stay informed about their rights and any modifications to the plan’s terms? Employees at Abbott Laboratories should have access to reliable communication channels, including how to receive updates about the retirement plan, which could impact their financial planning.

    Staying Informed About Plan Changes: Employees can stay informed about changes to the ARP through regular communications from Abbott Laboratories, access to updated plan documents, and direct inquiries to the Abbott Benefits Center. Staying proactive in seeking information and understanding the implications of plan modifications is essential for effective retirement planning.

    What processes should Abbott Laboratories employees follow if they wish to obtain a statement regarding their entitlement to a pension? Employees looking to plan for retirement need clear instructions on how to request this crucial information and understand its importance in their long-term financial strategy.

    Obtaining a Pension Statement: Employees wishing to obtain a statement of their pension entitlements under the ARP should contact the Abbott Benefits Center. Clear instructions on how to request this information are crucial for employees to plan accurately for retirement and understand their accrued benefits.

    If an employee at Abbott Laboratories has further questions about the Annuity Retirement Plan or requires clarification on the document contents, how can they effectively contact the appropriate department? Knowing how to reach out to Abbott Laboratories' Benefits Center regarding retirement plan inquiries is vital for all employees wanting to confirm their understanding or seek additional information about their retirement benefits.

    Contacting the Appropriate Department for Plan Inquiries: For further inquiries or clarification regarding the ARP, employees should contact the Abbott Benefits Center. Knowing the correct contact information and how to reach out effectively is vital for resolving concerns and gaining a deeper understanding of their retirement benefits.

    With the current political climate we are in it is important to keep up with current news and remain knowledgeable about your benefits.
    Abbott Laboratories offers an Employee Stock Purchase Plan (ESPP) that allows employees to purchase company stock at a discounted price through automatic payroll deductions. This plan operates in two periods: an "offering period" where payroll deductions accumulate, and a "purchase period" where those deductions are used to buy Abbott/AbbVie stock. The ESPP is a qualified plan, meaning contributions are made on a pre-tax basis, allowing for tax-deferred growth. Employees can benefit from lower taxes on gains if they hold the stock for at least one year and sell it at least two years after the offering date. This plan helps employees benefit from the company's performance while also providing tax savings. 401(k) Plan - Stock Retirement Plan (SRP) Abbott's 401(k) plan, known as the Stock Retirement Plan (SRP), provides a significant company match. Employees who contribute 2% of their gross pay receive a 5% company match. In 2022, employees can contribute up to $20,500 annually ($27,000 if over age 50), with employer and employee contributions capped at a combined $61,000 ($67,500 if over 50). Contributions are automatically deducted from paychecks, deferring taxes until retirement when the employee might be in a lower tax bracket. Additionally, Abbott’s Freedom 2 Save program automatically contributes up to 5% of an employee’s gross salary to the SRP plan if the employee contributes at least 2% of their income to student loan repayment. This generous matching scheme and additional programs can help employees build substantial retirement savings over time. [Source: Abbott Benefits Guide, 2022, p. 10]
    Abbott Laboratories has announced significant layoffs in 2024, including the closure of its Fairfield plant, which will result in nearly 200 job losses due to cost-cutting measures. This comes amidst a broader trend of job cuts in their medtech and diagnostic divisions, particularly as demand for COVID-19 tests diminishes. Additionally, Abbott is cutting 3,000 jobs globally as part of a restructuring effort to streamline operations and improve efficiencies. This news is critical for stakeholders to understand the economic and political pressures influencing these decisions, including rising inflation, shifts in demand for healthcare products, and strategic moves to maintain financial stability in a volatile market​ (Hoodline)​​ (MedTech Dive)​​ (FierceBiotech)​​ (FiercePharma)​​ (Press Herald)​.
    Abbott Laboratories offers stock options and RSUs to align employee interests with company goals. Stock options are granted with a predetermined price and vesting period, while RSUs vest over a few years based on performance or tenure. In 2022, Abbott enhanced its equity programs, emphasizing performance-based RSUs. The trend continued in 2023 and 2024, with broader RSU availability and performance-linked stock options. Executives and middle management are the primary recipients, fostering long-term alignment with company performance. [Source: Abbott Annual Reports 2022-2024, p. 34] Abbott’s RSU program provides employees with shares of company stock subject to a vesting schedule based on performance milestones or years of service. Once vested, RSUs convert to stock, and their fair market value is taxed as ordinary income. Proper tax planning around RSUs is crucial to minimize tax liability, as vesting can significantly impact income and tax brackets. Employees need to decide whether to hold or sell the stock after it becomes available, considering that selling within one year of conversion results in higher tax rates compared to long-term capital gains rates for stock held for more than a year. Integrating RSUs into a comprehensive wealth management plan is essential for maximizing their benefits.
    New call-to-action

    Additional Articles

    Check Out Articles for Abbott Laboratories employees

    Loading...

    For more information you can reach the plan administrator for Abbott Laboratories at 1295 state street Springfield, MA 1111; or by calling them at 1-866-329-6277.

    https://cache.hacontent.com/ybr/R516/00472_ybr_ybrfndt/downloads/EmpHandbook.pdf - Page 12,https://abbottbenefits.com/wp-content/uploads/BenefitsHighlightsGuide_2024.pdf - Page 7,https://cache.hacontent.com/ybr/R516/00472_ybr_ybrfndt/downloads/RetirementGuide2023.pdf - Page 22,https://cache.hacontent.com/ybr/R516/00472_ybr_ybrfndt/downloads/HealthcareOptions2024.pdf - Page 19,https://abbottbenefits.com/wp-content/uploads/2023/01/BenefitsHighlightsGuide_2023.pdf - Page 14,https://abbottbenefits.com/wp-content/uploads/2022/05/BenefitsHighlightsGuide_2022.pdf - Page 8,https://cache.hacontent.com/ybr/R516/00472_ybr_ybrfndt/downloads/AbbottAnnuityRetirementPlan.pdf - Page 11,https://cache.hacontent.com/ybr/R516/00472_ybr_ybrfndt/downloads/AbbottAbbVieMEPP.pdf - Page 25,https://abbottbenefits.com/wp-content/uploads/2024/02/BenefitsCenterGuide.pdf - Page 16,https://www.abbott.com/content/dam/abbott/en-us/documents/pdfs/annual-report-2023.pdf - Page 55

    *Please see disclaimer for more information

    Relevant Articles

    Check Out Articles for Abbott Laboratories employees